Barclays PLC Raises Stock Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Barclays PLC raised its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 147.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 89,650 shares of the biotechnology company's stock after acquiring an additional 53,354 shares during the period. Barclays PLC owned approximately 0.20% of Capricor Therapeutics worth $1,238,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in CAPR. Summit Investment Advisors Inc. raised its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 2,947 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter valued at $78,000. New York State Common Retirement Fund grew its holdings in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 5,000 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $91,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.62 during midday trading on Friday, reaching $6.35. The stock had a trading volume of 3,630,166 shares, compared to its average volume of 1,613,363. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The company's 50 day moving average price is $11.16 and its 200 day moving average price is $14.18. The firm has a market cap of $290.05 million, a price-to-earnings ratio of -5.99 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Equities analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CAPR shares. HC Wainwright reiterated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.